Broadcast Date: February 17th, 2015
Time: 11:00 am ET, 8:00 am PT
Interest in exosomes has seen resurgence in the past several years. After their initial discovery more than 30 years ago, they were seen as mere molecular dumpsters. But recent evidence has shown that these tiny vesicles can act as messengers, transporting their payloads of proteins, lipids, and genetic material to distant tissues where they can alter cellular function. Moreover, their ability to serve as a minimally invasive diagnostic tool could prove to be invaluable for the identification and treatment of cancer.
In this webinar, Aled Clayton, Ph.D., principal investigator within the tumor immunology group at the Institute of Cancer and Genetics for Cardiff University School of Medicine, will describe his novel approach to examining the intricate composition of exosomes and how his technique may be applied to clinical diagnostics.
Stephen Williams, M.D., Ph.D., chief medical officer for SomaLogic, will address the nature of the SOMAscan technology and how it has been successfully applied by numerous research groups to answer disease-specific proteomic questions in a high-throughput manner.
Who Should Attend
- R & D scientists
- Proteomics scientists
- Vesicle biology researchers
- Translational research scientists
- Cancer biology researchers
You Will Learn
- How exosomes are formed and why they are important for disease.
- The complex contents and function of exosomes and their important role in cancer biology.
- How SomaLogic’s proteomic platform technology was able to enhance exosome analysis and improve analysis sensitivity.
- What can be gained by using SOMAscan to understand the proteomics of exosomes.
Produced with support from:
Aled Clayton, Ph.D.
Cardiff University School of Medicine
Stephen Williams, M.D., Ph.D.
Chief Medical Officer,